- Home
- MIRM vs MORN Comparison
MIRM vs MORN Comparison
Compare MIRM & MORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIRM | MORN |
|---|---|---|
| Founded | 2018 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.2B |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | MIRM | MORN |
|---|---|---|
| Price | $97.80 | $216.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | $119.85 | ★ $256.50 |
| AVG Volume (30 Days) | ★ 649.6K | 289.1K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.07% |
| EPS Growth | ★ 74.59 | 3.38 |
| EPS | N/A | ★ 5.55 |
| Revenue | $19,138,000.00 | ★ $2,445,500,000.00 |
| Revenue This Year | $26.22 | $9.14 |
| Revenue Next Year | $22.04 | $7.23 |
| P/E Ratio | ★ N/A | $39.43 |
| Revenue Growth | N/A | ★ 7.49 |
| 52 Week Low | $63.23 | $141.49 |
| 52 Week High | $130.00 | $261.76 |
Technical Indicators
Market Signals| Indicator | MIRM | MORN |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 68.95 |
| Support Level | $88.08 | $207.94 |
| Resistance Level | $98.03 | $220.51 |
| Average True Range (ATR) | 3.30 | 6.60 |
| MACD | 0.33 | -0.05 |
| Stochastic Oscillator | 24.02 | 91.28 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About MORN Morningstar Inc.
Morningstar Inc is a provider of independent investment insights to financial advisers, asset managers, and investors. It provides data and research insights on various investment offerings, including managed investment products, publicly listed companies, private capital markets, debt securities, and real-time market data. The company has five reportable segments: Morningstar Direct Platform, PitchBook, Morningstar Credit, Morningstar Wealth, and Morningstar Retirement. Maximum revenue is derived from the Morningstar Direct Platform, which provides investors with comprehensive data, research, insights, and investment analysis through product areas such as Morningstar Data, Morningstar Direct, and Morningstar Advisor Workstation. Geographically, it generates maximum revenue from the USA.